Old dogma, new tricks - 21st Century phage therapy

Nature Biotechnology

Volumn 22, Issue 1, 2004, Pages 31-36

  Thiel, Karl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; BACTERIOPHAGES; HEALTH RISKS;

PHAGE THERAPY;

BIOTECHNOLOGY;

ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; BIOTECHNOLOGY; FOOD AND DRUG ADMINISTRATION; LIFE CYCLE; PRIORITY JOURNAL; REVIEW;

BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; BIOPHARMACEUTICS; BIOTECHNOLOGY; CROPS, AGRICULTURAL; DNA; DRUG RESISTANCE, BACTERIAL; MICROSCOPY, ELECTRON; TECHNOLOGY, PHARMACEUTICAL;

UNIDENTIFIED BACTERIOPHAGE;

EID: 0347356354     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0104-31     Document Type: Review

References (5)

1. US Centers for Disease Control, the Food and Drug Administration and the US National Institutes of Health. A Public Health Action Plan to Combat Antimicrobial Resistance (CDC, FDA & NIH, June, 2000) (http://www.cdc.gov/drugresistance/actionplan/aractionplan.pdf).
2. S. Tslodras et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001).
3. G.M. Eliopoulos, et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrobial Agents Chemother. 42, 1088-1092 (1998).
4. Fox, J. Concerns raised over declining antiinfective R&D. Nat. Biotechnol. 21, 1255-1256 (2003).
5. Scholl, D. et al. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 75, 2509-2515 (2001).